ZDHHC9 and adenocarcinoma: These findings expand the current understanding of how distinct ZDHHC enzymes converge on the Hippo/YAP pathway via different molecular entry points, highlighting DHHC9–STRN4 as a complementary and previously unrecognised regulatory axis with therapeutic potential in adenocarcinoma metastasis.